SCHEMBL2277293

SCHEMBL2277293

COC(=O)CNC(=O)c1ccc(C=CC(=O)c2c(O)cc(C)n(C)c2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.43
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SLC5A1 P13866 3/20 0.41
SLC5A2 P31639 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
DPP4 P27487 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277289 1.00 APP (0.43) APPKDM4EMEN1TSHRKMT2A
SCHEMBL2280532 0.90 SLC5A1 (0.42) APPMEN1KMT2ASLC5A1SLC5A2
SCHEMBL2280535 0.90 SLC5A1 (0.42) APPMEN1KMT2ASLC5A1SLC5A2
SCHEMBL2281269 0.89 P4HB (0.41) MEN1KMT2ASMN1; SMN2CYP2C19NPC1
SCHEMBL2281265 0.89 P4HB (0.41) MEN1KMT2ASMN1; SMN2CYP2C19NPC1
SCHEMBL2279763 0.89 ABCG2 (0.45) APPKDM4EMEN1TSHRKMT2A
SCHEMBL2279768 0.89 ABCG2 (0.45) APPKDM4EMEN1TSHRKMT2A
SCHEMBL2284527 0.83 LMNA (0.50) APPKDM4EMEN1TSHRKMT2A
SCHEMBL2284522 0.83 LMNA (0.50) APPKDM4EMEN1TSHRKMT2A
SCHEMBL2281403 0.81 ABCG2 (0.45) APPKDM4EMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 APP 3864/4885KDM4E 2443/4885MEN1 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.